Reduced survival in adult cystic fibrosis despite attenuated lung function decline

Abstract Background There is limited data on disease progression and survival in adult diagnosis cystic fibrosis (CF). This study evaluates change of lung function over time and rates of death/lung transplant in adult diagnosis CF. Methods The CF Foundation Patient Registry was reviewed for patients...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of cystic fibrosis 2017-01, Vol.16 (1), p.78-84
Hauptverfasser: Keating, Claire, Poor, Armeen D, Liu, Xinhua, Chiuzan, Codruta, Backenroth, Daniel, Zhang, Yuan, DiMango, Emily
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 84
container_issue 1
container_start_page 78
container_title Journal of cystic fibrosis
container_volume 16
creator Keating, Claire
Poor, Armeen D
Liu, Xinhua
Chiuzan, Codruta
Backenroth, Daniel
Zhang, Yuan
DiMango, Emily
description Abstract Background There is limited data on disease progression and survival in adult diagnosis cystic fibrosis (CF). This study evaluates change of lung function over time and rates of death/lung transplant in adult diagnosis CF. Methods The CF Foundation Patient Registry was reviewed for patients diagnosed 1993–2003. Rate of FEV1 decline was calculated up to 2010 for age groups 6–11, 12–17, and 18 and above. Kaplan Meier method was used for 10 and 15 year survival rate calculations for patients diagnosed as adults. Cox Proportional hazards models using predictors affecting disease progression and survival without transplant were run. Results Between 1993 and 2003, 11,884 patients were diagnosed with CF, of which 2848 were ages 6 and older. Annual rate of change of FEV1% predicted over 5 years differed by diagnosis age group: − 1.42% per year for ages 6–11, − 2.04% for ages 12–17 and − 1.13% for ages 18–65 (p < 0.0001). Pseudomonas aeruginosa infection was associated with faster rates of lung function decline in all age groups. Survival without transplant for CF patients diagnosed at ≥ 18 years were 76% and 65% by 10 and 15 years, respectively. Of adults with FEV1 of > 70% predicted at diagnosis, 95% were alive without transplant at 10 years, whereas of those with FEV1 < 40% predicted at diagnosis, 31% were alive without transplant at 10 years. Conclusions Lung function declines at a slower rate in adult diagnosis CF. However, particularly in those with low lung function at diagnosis, rates of death or transplant in adult diagnosis CF after 10 and 15 years is not negligible.
doi_str_mv 10.1016/j.jcf.2016.07.012
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1859723981</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1569199316305690</els_id><sourcerecordid>1859723981</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-a8e58ba4f7bf392de93f8b6975c1adc78287179613d1474811a0f6383742dd8a3</originalsourceid><addsrcrecordid>eNp9kU-L1TAUxYM4OOPoB3AjXbppzU3aJkEQZFBnYECYP-uQJreS2pc-m-TB-_aT8kYXLlzdszjnwP0dQt4BbYBC_3FqJjs2rMiGioYCe0EuQApedxToy6K7XtWgFD8nr2OcKAVBhXxFzpnoGOMAF-TuDl226KqY14M_mLnyoTIuz6myx5i8rUY_rEv0sXIY9z5hZVLCkE0qoTmHn9WYg01-CcVgZx_wDTkbzRzx7fO9JI_fvj5cXde3P77fXH25rW3bQaqNxE4Oph3FMHLFHCo-yqFXorNgnBWSSQFC9cAdtKKVAIaOPZdctMw5afgl-XDq3a_L74wx6Z2PFufZBFxy1CA7JRhXEooVTlZbXokrjnq_-p1Zjxqo3lDqSReUekOpqdAFZcm8f67Pww7d38QfdsXw6WTA8uTB46qj9RgKTL-iTdot_r_1n_9Jb_C8NfMvPGKclryGQk-DjkxTfb9tuU0JPadFUv4EyWKY-Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1859723981</pqid></control><display><type>article</type><title>Reduced survival in adult cystic fibrosis despite attenuated lung function decline</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Keating, Claire ; Poor, Armeen D ; Liu, Xinhua ; Chiuzan, Codruta ; Backenroth, Daniel ; Zhang, Yuan ; DiMango, Emily</creator><creatorcontrib>Keating, Claire ; Poor, Armeen D ; Liu, Xinhua ; Chiuzan, Codruta ; Backenroth, Daniel ; Zhang, Yuan ; DiMango, Emily</creatorcontrib><description>Abstract Background There is limited data on disease progression and survival in adult diagnosis cystic fibrosis (CF). This study evaluates change of lung function over time and rates of death/lung transplant in adult diagnosis CF. Methods The CF Foundation Patient Registry was reviewed for patients diagnosed 1993–2003. Rate of FEV1 decline was calculated up to 2010 for age groups 6–11, 12–17, and 18 and above. Kaplan Meier method was used for 10 and 15 year survival rate calculations for patients diagnosed as adults. Cox Proportional hazards models using predictors affecting disease progression and survival without transplant were run. Results Between 1993 and 2003, 11,884 patients were diagnosed with CF, of which 2848 were ages 6 and older. Annual rate of change of FEV1% predicted over 5 years differed by diagnosis age group: − 1.42% per year for ages 6–11, − 2.04% for ages 12–17 and − 1.13% for ages 18–65 (p &lt; 0.0001). Pseudomonas aeruginosa infection was associated with faster rates of lung function decline in all age groups. Survival without transplant for CF patients diagnosed at ≥ 18 years were 76% and 65% by 10 and 15 years, respectively. Of adults with FEV1 of &gt; 70% predicted at diagnosis, 95% were alive without transplant at 10 years, whereas of those with FEV1 &lt; 40% predicted at diagnosis, 31% were alive without transplant at 10 years. Conclusions Lung function declines at a slower rate in adult diagnosis CF. However, particularly in those with low lung function at diagnosis, rates of death or transplant in adult diagnosis CF after 10 and 15 years is not negligible.</description><identifier>ISSN: 1569-1993</identifier><identifier>EISSN: 1873-5010</identifier><identifier>DOI: 10.1016/j.jcf.2016.07.012</identifier><identifier>PMID: 27522311</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adult ; Adult diagnosis cystic fibrosis ; Cystic fibrosis ; Cystic Fibrosis - diagnosis ; Cystic Fibrosis - microbiology ; Cystic Fibrosis - mortality ; Cystic Fibrosis - physiopathology ; Disease Progression ; Female ; Forced Expiratory Volume ; Humans ; Kaplan-Meier Estimate ; Lung function ; Lung Transplantation - statistics &amp; numerical data ; Male ; Prognosis ; Proportional Hazards Models ; Pseudomonas Infections - diagnosis ; Pseudomonas Infections - epidemiology ; Pseudomonas Infections - physiopathology ; Pulmonary/Respiratory ; Respiratory Tract Infections - diagnosis ; Respiratory Tract Infections - epidemiology ; Respiratory Tract Infections - physiopathology ; Survival ; Survival Rate ; United States - epidemiology</subject><ispartof>Journal of cystic fibrosis, 2017-01, Vol.16 (1), p.78-84</ispartof><rights>European Cystic Fibrosis Society.</rights><rights>2016 European Cystic Fibrosis Society.</rights><rights>Copyright © 2016 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c451t-a8e58ba4f7bf392de93f8b6975c1adc78287179613d1474811a0f6383742dd8a3</citedby><cites>FETCH-LOGICAL-c451t-a8e58ba4f7bf392de93f8b6975c1adc78287179613d1474811a0f6383742dd8a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1569199316305690$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27522311$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Keating, Claire</creatorcontrib><creatorcontrib>Poor, Armeen D</creatorcontrib><creatorcontrib>Liu, Xinhua</creatorcontrib><creatorcontrib>Chiuzan, Codruta</creatorcontrib><creatorcontrib>Backenroth, Daniel</creatorcontrib><creatorcontrib>Zhang, Yuan</creatorcontrib><creatorcontrib>DiMango, Emily</creatorcontrib><title>Reduced survival in adult cystic fibrosis despite attenuated lung function decline</title><title>Journal of cystic fibrosis</title><addtitle>J Cyst Fibros</addtitle><description>Abstract Background There is limited data on disease progression and survival in adult diagnosis cystic fibrosis (CF). This study evaluates change of lung function over time and rates of death/lung transplant in adult diagnosis CF. Methods The CF Foundation Patient Registry was reviewed for patients diagnosed 1993–2003. Rate of FEV1 decline was calculated up to 2010 for age groups 6–11, 12–17, and 18 and above. Kaplan Meier method was used for 10 and 15 year survival rate calculations for patients diagnosed as adults. Cox Proportional hazards models using predictors affecting disease progression and survival without transplant were run. Results Between 1993 and 2003, 11,884 patients were diagnosed with CF, of which 2848 were ages 6 and older. Annual rate of change of FEV1% predicted over 5 years differed by diagnosis age group: − 1.42% per year for ages 6–11, − 2.04% for ages 12–17 and − 1.13% for ages 18–65 (p &lt; 0.0001). Pseudomonas aeruginosa infection was associated with faster rates of lung function decline in all age groups. Survival without transplant for CF patients diagnosed at ≥ 18 years were 76% and 65% by 10 and 15 years, respectively. Of adults with FEV1 of &gt; 70% predicted at diagnosis, 95% were alive without transplant at 10 years, whereas of those with FEV1 &lt; 40% predicted at diagnosis, 31% were alive without transplant at 10 years. Conclusions Lung function declines at a slower rate in adult diagnosis CF. However, particularly in those with low lung function at diagnosis, rates of death or transplant in adult diagnosis CF after 10 and 15 years is not negligible.</description><subject>Adult</subject><subject>Adult diagnosis cystic fibrosis</subject><subject>Cystic fibrosis</subject><subject>Cystic Fibrosis - diagnosis</subject><subject>Cystic Fibrosis - microbiology</subject><subject>Cystic Fibrosis - mortality</subject><subject>Cystic Fibrosis - physiopathology</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Forced Expiratory Volume</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Lung function</subject><subject>Lung Transplantation - statistics &amp; numerical data</subject><subject>Male</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Pseudomonas Infections - diagnosis</subject><subject>Pseudomonas Infections - epidemiology</subject><subject>Pseudomonas Infections - physiopathology</subject><subject>Pulmonary/Respiratory</subject><subject>Respiratory Tract Infections - diagnosis</subject><subject>Respiratory Tract Infections - epidemiology</subject><subject>Respiratory Tract Infections - physiopathology</subject><subject>Survival</subject><subject>Survival Rate</subject><subject>United States - epidemiology</subject><issn>1569-1993</issn><issn>1873-5010</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU-L1TAUxYM4OOPoB3AjXbppzU3aJkEQZFBnYECYP-uQJreS2pc-m-TB-_aT8kYXLlzdszjnwP0dQt4BbYBC_3FqJjs2rMiGioYCe0EuQApedxToy6K7XtWgFD8nr2OcKAVBhXxFzpnoGOMAF-TuDl226KqY14M_mLnyoTIuz6myx5i8rUY_rEv0sXIY9z5hZVLCkE0qoTmHn9WYg01-CcVgZx_wDTkbzRzx7fO9JI_fvj5cXde3P77fXH25rW3bQaqNxE4Oph3FMHLFHCo-yqFXorNgnBWSSQFC9cAdtKKVAIaOPZdctMw5afgl-XDq3a_L74wx6Z2PFufZBFxy1CA7JRhXEooVTlZbXokrjnq_-p1Zjxqo3lDqSReUekOpqdAFZcm8f67Pww7d38QfdsXw6WTA8uTB46qj9RgKTL-iTdot_r_1n_9Jb_C8NfMvPGKclryGQk-DjkxTfb9tuU0JPadFUv4EyWKY-Q</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Keating, Claire</creator><creator>Poor, Armeen D</creator><creator>Liu, Xinhua</creator><creator>Chiuzan, Codruta</creator><creator>Backenroth, Daniel</creator><creator>Zhang, Yuan</creator><creator>DiMango, Emily</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170101</creationdate><title>Reduced survival in adult cystic fibrosis despite attenuated lung function decline</title><author>Keating, Claire ; Poor, Armeen D ; Liu, Xinhua ; Chiuzan, Codruta ; Backenroth, Daniel ; Zhang, Yuan ; DiMango, Emily</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-a8e58ba4f7bf392de93f8b6975c1adc78287179613d1474811a0f6383742dd8a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Adult diagnosis cystic fibrosis</topic><topic>Cystic fibrosis</topic><topic>Cystic Fibrosis - diagnosis</topic><topic>Cystic Fibrosis - microbiology</topic><topic>Cystic Fibrosis - mortality</topic><topic>Cystic Fibrosis - physiopathology</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Forced Expiratory Volume</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Lung function</topic><topic>Lung Transplantation - statistics &amp; numerical data</topic><topic>Male</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Pseudomonas Infections - diagnosis</topic><topic>Pseudomonas Infections - epidemiology</topic><topic>Pseudomonas Infections - physiopathology</topic><topic>Pulmonary/Respiratory</topic><topic>Respiratory Tract Infections - diagnosis</topic><topic>Respiratory Tract Infections - epidemiology</topic><topic>Respiratory Tract Infections - physiopathology</topic><topic>Survival</topic><topic>Survival Rate</topic><topic>United States - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Keating, Claire</creatorcontrib><creatorcontrib>Poor, Armeen D</creatorcontrib><creatorcontrib>Liu, Xinhua</creatorcontrib><creatorcontrib>Chiuzan, Codruta</creatorcontrib><creatorcontrib>Backenroth, Daniel</creatorcontrib><creatorcontrib>Zhang, Yuan</creatorcontrib><creatorcontrib>DiMango, Emily</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cystic fibrosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Keating, Claire</au><au>Poor, Armeen D</au><au>Liu, Xinhua</au><au>Chiuzan, Codruta</au><au>Backenroth, Daniel</au><au>Zhang, Yuan</au><au>DiMango, Emily</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reduced survival in adult cystic fibrosis despite attenuated lung function decline</atitle><jtitle>Journal of cystic fibrosis</jtitle><addtitle>J Cyst Fibros</addtitle><date>2017-01-01</date><risdate>2017</risdate><volume>16</volume><issue>1</issue><spage>78</spage><epage>84</epage><pages>78-84</pages><issn>1569-1993</issn><eissn>1873-5010</eissn><abstract>Abstract Background There is limited data on disease progression and survival in adult diagnosis cystic fibrosis (CF). This study evaluates change of lung function over time and rates of death/lung transplant in adult diagnosis CF. Methods The CF Foundation Patient Registry was reviewed for patients diagnosed 1993–2003. Rate of FEV1 decline was calculated up to 2010 for age groups 6–11, 12–17, and 18 and above. Kaplan Meier method was used for 10 and 15 year survival rate calculations for patients diagnosed as adults. Cox Proportional hazards models using predictors affecting disease progression and survival without transplant were run. Results Between 1993 and 2003, 11,884 patients were diagnosed with CF, of which 2848 were ages 6 and older. Annual rate of change of FEV1% predicted over 5 years differed by diagnosis age group: − 1.42% per year for ages 6–11, − 2.04% for ages 12–17 and − 1.13% for ages 18–65 (p &lt; 0.0001). Pseudomonas aeruginosa infection was associated with faster rates of lung function decline in all age groups. Survival without transplant for CF patients diagnosed at ≥ 18 years were 76% and 65% by 10 and 15 years, respectively. Of adults with FEV1 of &gt; 70% predicted at diagnosis, 95% were alive without transplant at 10 years, whereas of those with FEV1 &lt; 40% predicted at diagnosis, 31% were alive without transplant at 10 years. Conclusions Lung function declines at a slower rate in adult diagnosis CF. However, particularly in those with low lung function at diagnosis, rates of death or transplant in adult diagnosis CF after 10 and 15 years is not negligible.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>27522311</pmid><doi>10.1016/j.jcf.2016.07.012</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1569-1993
ispartof Journal of cystic fibrosis, 2017-01, Vol.16 (1), p.78-84
issn 1569-1993
1873-5010
language eng
recordid cdi_proquest_miscellaneous_1859723981
source MEDLINE; Elsevier ScienceDirect Journals Complete; EZB-FREE-00999 freely available EZB journals
subjects Adult
Adult diagnosis cystic fibrosis
Cystic fibrosis
Cystic Fibrosis - diagnosis
Cystic Fibrosis - microbiology
Cystic Fibrosis - mortality
Cystic Fibrosis - physiopathology
Disease Progression
Female
Forced Expiratory Volume
Humans
Kaplan-Meier Estimate
Lung function
Lung Transplantation - statistics & numerical data
Male
Prognosis
Proportional Hazards Models
Pseudomonas Infections - diagnosis
Pseudomonas Infections - epidemiology
Pseudomonas Infections - physiopathology
Pulmonary/Respiratory
Respiratory Tract Infections - diagnosis
Respiratory Tract Infections - epidemiology
Respiratory Tract Infections - physiopathology
Survival
Survival Rate
United States - epidemiology
title Reduced survival in adult cystic fibrosis despite attenuated lung function decline
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T23%3A08%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reduced%20survival%20in%20adult%20cystic%20fibrosis%20despite%20attenuated%20lung%20function%20decline&rft.jtitle=Journal%20of%20cystic%20fibrosis&rft.au=Keating,%20Claire&rft.date=2017-01-01&rft.volume=16&rft.issue=1&rft.spage=78&rft.epage=84&rft.pages=78-84&rft.issn=1569-1993&rft.eissn=1873-5010&rft_id=info:doi/10.1016/j.jcf.2016.07.012&rft_dat=%3Cproquest_cross%3E1859723981%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1859723981&rft_id=info:pmid/27522311&rft_els_id=1_s2_0_S1569199316305690&rfr_iscdi=true